Filing Details

Accession Number:
0000899243-15-008448
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-11-18 19:55:39
Reporting Period:
2015-08-14
Filing Date:
2015-11-18
Accepted Time:
2015-11-18 19:55:39
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1631574 Wave Life Sciences Ltd. WVE Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1657768 Ken Takanashi C/o Shin Nippon Biomedical Laboratories,
2438 Miyanoura-Machi, Kagoshima City
Kagoshima M0 891-1394
Yes No Yes No
1657770 Shin Nippon Biomedical Laboratories, Ltd. 2438 Miyanoura-Machi, Kagoshima City
Kagoshima M0 891-1394
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2015-11-16 161,663 $0.00 1,859,130 No 4 C Indirect See Footnote
Ordinary Shares Acquisiton 2015-11-16 125,000 $16.00 1,984,130 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See Footnote
No 4 P Indirect See Footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Series B Preferred Shares Acquisiton 2015-08-14 161,663 $12.37 161,663 $0.00
Ordinary Shares Series B Preferred Shares Disposition 2015-11-16 161,663 $0.00 161,663 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
161,663 No 4 P Indirect
0 No 4 C Indirect
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Ordinary Shares Series A Preferred Shares $0.00 3,901,348 3,901,348 Indirect
Expiration Date Amount Remaning Holdings Nature of Ownership
3,901,348 3,901,348 Indirect
Footnotes
  1. Shares held by SNBL USA, Ltd. ("SNBL USA"), an affiliate of Shin Nippon Biomedical Laboratories, Ltd. ("SNBL"). Ken Takanashi, a director of the Issuer, is a director of SNBL and SNBL USA and each of Mr. Takanashi and SNBL may be deemed to beneficially own the reported securities held by SNBL USA.
  2. The Series B Preferred Shares automatically converted into Ordinary Shares on a one-for-one basis upon the closing of the Issuer's initial public offering of its Ordinary Shares.
  3. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), Mr. Takanashi and SNBL each disclaim beneficial ownership of the reported securities held by SNBL USA, and Mr. Takanashi disclaims beneficial ownership of the reported securities held by SNBL, in each case except to the extent of his or its respective pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Takanashi is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities held by SNBL or SNBL USA. The filing of this Form 4 shall not be construed as an admission that SNBL is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities held by SNBL USA.
  4. The reported shares are held as follows; 1,697,467 shares are held by SNBL and 286,663 shares are held by SNBL USA.
  5. The Series A Preferred Shares are convertible into Ordinary Shares on a one-for-one basis at any time at the option of the holder and have no expiration date.
  6. Shares held by SNBL.
  7. Share amounts reflect a 4.0415917-for-1 forward split of the Issuer's shares on November 1, 2015. The securities were purchased for $12.37 per share on a post-split basis.